Recent advances in proton pump inhibitors and management of acid-peptic disorders

被引：98

作者：

Jain, Kishor S. ^{[1
]}

Shah, Anamik K.

Bariwal, Jitender

Shelke, Suhas M.

Kale, Amol P.

Jagtap, Jayshree R.

Bhosale, Ashok V.

机构：

[1] Sinhgad Coll Pharm, Pune 411041, Maharashtra, India

[2] Saurashtra Univ, Dept Chem, Rajkot 360005, Gujarat, India

[3] SGRS Coll Pharm, Pune 412301, Maharashtra, India

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2007年 / 15卷 / 03期

关键词：

acid-peptic disorders; therapeutic strategies; gastric H+/K+-ATPase (proton pump); proton pump inhibitors (PPIs); acid pump antagonist (APAs); HELICOBACTER-PYLORI INFECTION; H+/K+-ATPASE INHIBITORS; REVERSIBLE INHIBITORS; GASTRIC (H+/K+)-ATPASE; H+; K+-ATPASE INHIBITOR; DUODENAL-ULCER; ANTIULCER ACTIVITY; SECRETION; PHARMACOKINETICS; LANSOPRAZOLE;

D O I：

10.1016/j.bmc.2006.07.068

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Acid-peptic ulcers and diseases have been increasingly on rise in today's era of globalization, which is characterized by hurry, worry, and curry. This review summarizes various disorders associated with increased gastric acid secretion and various therapeutic strategies to control them. The emphasis has been laid, in particular, on the role of proton pump inhibitors (PPIs) widely used nowadays for the treatment of gastric acid diseases. The medicinal chemistry aspects and mechanism of action of irreversible PPIs and APAs have been discussed at molecular levels. The ongoing research status in this field has also been covered. Further, biological evaluation methods that can be used for screening of PPIs are also discussed in short. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：1181 / 1205

页数：25

共 116 条

[1]

PHARMACOKINETICS AND BIOAVAILABILITY OF OMEPRAZOLE AFTER SINGLE AND REPEATED ORAL-ADMINISTRATION IN HEALTHY-SUBJECTS [J].

ANDERSSON, T ;

ANDREN, K ;

CEDERBERG, C ;

LAGERSTROM, PO ;

LUNDBORG, P ;

SKANBERG, I .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (05) :557-563

[2]

Beyond gastric acid reduction:: Proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells [J].

Becker, Jan C. ;

Grosser, Nina ;

Waltke, Christian ;

Schulz, Stephanie ;

Erdmann, Kati ;

Domschke, Wolfram ;

Schroeder, Henning ;

Pohle, Thorsten .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 345 (03) :1014-1021

[3]

BERARDI RR, 1998, CLIN PHARM, V7, P271

[4]

BERZSENYI E, 1995, PHARM RES, V31, P94

[5]

BICKEL M, 2002, DRUG DISCOVERY EVALU, P861

[6]

4-substituted 1-(2-methylphenyl)thieno[2,3-c]-1,5-naphthyridines as possible reversible inhibitors of gastric H+,K+-ATPase [J].

Bjork, P ;

Hornfeldt, AB ;

Gronowitz, S ;

Edvardsson, U .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1996, 31 (05) :411-416

[7]

DEFINITION AND ANTAGONISM OF HISTAMINE H2-RECEPTORS [J].

BLACK, JW ;

PARSONS, EM ;

DURANT, CJ ;

DUNCAN, WAM ;

GANELLIN, CR .

NATURE, 1972, 236 (5347) :385-&

[8]

BRITTAIN RT, 1981, SCAN J GASTROENTEROL, V69, P129

[9]

HETEROCYCLIC AMPLIFIERS OF PHLEOMYCIN .1. SOME PYRIMIDINYLPURINES, PYRIMIDINYLPTERIDINES AND PHENYLPYRIMIDINES [J].

BROWN, DJ ;

COWDEN, WB ;

LAN, SB ;

MORI, K .

AUSTRALIAN JOURNAL OF CHEMISTRY, 1984, 37 (01) :155-163

[10]

REVERSIBLE INHIBITORS OF THE GASTRIC (H+/K+)-ATPASE .1. 1-ARYL-4-METHYLPYRROLO[3,2-C]QUINOLINES AS CONFORMATIONALLY RESTRAINED ANALOGS OF 4-(ARYLAMINO)QUINOLINES [J].

BROWN, TH ;

IFE, RJ ;

KEELING, DJ ;

LAING, SM ;

LEACH, CA ;

PARSONS, ME ;

PRICE, CA ;

REAVILL, DR ;

WIGGALL, KJ .

JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (02) :527-533

← 1 2 3 4 5 6 7 8 9 10 →